- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | OncoZenge AB: OncoZenge Confirms Submission of Responses to EMA on the BupiZenge Phase III Trial (BZ003) | 72 | GlobeNewswire (Europe) | OncoZenge AB (publ), OncoZenge or "the Company", developing innovative treatments for oral pain management, today announced the complete submission of responses to European authorities' Requests for... ► Artikel lesen | |
| 01.04. | OncoZenge AB: OncoZenge Reports Positive Stability Results for BupiZenge as Key Enabler for the Upcoming Phase III Trial | 75 | GlobeNewswire (Europe) | OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the three-month stability study results for its BupiZenge lozenge are within... ► Artikel lesen | |
| 26.02. | OncoZenge AB: OncoZenge AB Year-end Report January 1 - December 31, 2025 | 115 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced its full year report for 2025, a year of significant progress culminating in the submission of the Phase III Clinical Trial Application... ► Artikel lesen | |
| 12.02. | OncoZenge AB: OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical | 239 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the third tranche of investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the "Investor").
The investment... ► Artikel lesen | |
| 02.02. | OncoZenge AB: OncoZenge AB Appoints Dr. Marie-Louise Fjällskog as Chief Medical Officer | 269 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company"), a clinical-stage pharmaceutical company developing innovative treatments for oral pain, today announced the appointment of Dr. Marie-Louise Fjällskog, MD, PhD, as... ► Artikel lesen | |
| 30.01. | OncoZenge AB: OncoZenge AB Reports Positive Initial Stability Results for the BupiZenge Technology Batch, Advancing Toward Clinical Trials | 152 | GlobeNewswire (Europe) | OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the one-month stability study results for its BupiZenge lozenge technology... ► Artikel lesen | |
| ONCOZENGE Aktie jetzt für 0€ handeln | |||||
| 22.01. | OncoZenge AB: OncoZenge enters into convertible loan agreement with Linc AB and gives an update on the payment of subscription proceeds | 477 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or the "Company") has today entered into an agreement for a bridge financing solution of SEK 5 million, via a convertible note with Linc AB ("Linc") to be repaid upon... ► Artikel lesen | |
| 22.01. | OncoZenge AB receives observation status | 188 | GlobeNewswire | Yesterday, January 21, 2026, OncoZenge AB (the "Company") disclosed a press release with information about uncertainties regarding the payment of the subscription proceeds in a previously announced... ► Artikel lesen | |
| 21.01. | OncoZenge AB: OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact | 266 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company") has just been informed that the strategic investor Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the "Investor") will not be able to pay the subscription proceeds... ► Artikel lesen | |
| 19.12.25 | OncoZenge AB: OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement | 182 | GlobeNewswire (Europe) | The information contained in this press release is not for publication, release or distribution, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand... ► Artikel lesen | |
| 03.12.25 | OncoZenge AB: OncoZenge and Molteni expand partnership: Molteni to assume commercial manufacturing of BupiZenge for Europe | 144 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or the "Company"), a pharmaceutical company developing BupiZenge, an innovative non-opioid therapy for treating oral pain, today announces an amended agreement with... ► Artikel lesen | |
| 17.11.25 | OncoZenge AB: OncoZenge Strengthens Advisory Board with Co-Inventor Dr. Torben Mogensen Ahead of Phase III Trial for BupiZenge | 203 | GlobeNewswire (Europe) | OncoZenge AB (publ) (Nasdaq First North Growth Market: ONCOZ), a pharmaceutical company developing BupiZenge, an innovative non-opioid therapy for treating oral pain, today announces the addition of... ► Artikel lesen | |
| 30.10.25 | OncoZenge AB: OncoZenge AB Interim Report January 1 - September 30, 2025 | 383 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the third quarter of 2025. The Company reports receipt of investment funds for its European Phase III program... ► Artikel lesen | |
| 09.10.25 | OncoZenge AB: OncoZenge AB: First Patient Enrolled in UCLA Patient Engagement Study | 162 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a pharmaceutical company developing an innovative treatment for oral pain relief, today announced that University of California, Los Angeles (UCLA)... ► Artikel lesen | |
| 17.09.25 | OncoZenge AB: OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge | 189 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a pharmaceutical company developing an innovative treatment for oral pain relief, today announced a new collaboration with the University of California... ► Artikel lesen | |
| 10.09.25 | OncoZenge AB: OncoZenge AB appoints LINK Medical as CRO for BupiZenge Phase III execution | 546 | GlobeNewswire (Europe) | OncoZenge AB has selected LINK Medical, a Nordic-based clinical research organization (CRO), to lead the Phase III trial for BupiZenge, its innovative drug candidate designed to relieve oral pain from... ► Artikel lesen | |
| 21.08.25 | OncoZenge AB: OncoZenge AB Interim Report January 1 - June 30, 2025 | 273 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the second quarter of 2025. The Company's Phase III program has moved into execution. Preparations are now underway... ► Artikel lesen | |
| 30.07.25 | OncoZenge AB: OncoZenge Provides Market and Strategy Update | 492 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge Phase 3 clinical trial aimed... ► Artikel lesen | |
| 21.07.25 | OncoZenge AB: OncoZenge Appoints Meribel Pharma as CDMO for BupiZenge Phase 3 Project | 201 | GlobeNewswire (Europe) | OncoZenge AB ("OncoZenge" or "the Company") today announced it has engaged Meribel Pharma Solutions ("Meribel," formerly Recipharm) as its Contract Development and Manufacturing Organization (CDMO)... ► Artikel lesen | |
| 17.07.25 | OncoZenge AB: OncoZenge and Molteni Farmaceutici Sign Amendment to Focus BupiZenge Phase 3 Project in Europe | 260 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the signing of an amendment to the license and supply agreement with Molteni Farmaceutici. This amendment accelerates certain milestones... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 34,895 | +1,10 % | Novo Nordisk: Offensive im Abnehm-Markt - und ein Vorteil im Datencheck | Novo Nordisk drückt weiter aufs Gaspedal. Das Unternehmen hat die nächste Ausbaustufe seines Abnehm-Blockbusters an den Start gebracht: Seit Dienstag ist in den USA die neue Hochdosis-Variante Wegovy... ► Artikel lesen | |
| ASTRAZENECA | 169,90 | -0,41 % | JEFFERIES stuft ASTRAZENECA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Astrazeneca mit einem Kursziel von 18000 Pence auf "Buy" belassen. Operative Aufwendungen dürften belastet haben, schrieb Michael Leuchten... ► Artikel lesen | |
| CAMURUS | 51,55 | +3,39 % | Camurus AB: Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer | Lund, Sweden - 17 February 2026 - Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed as Camurus' Chief Corporate Development Officer (CCDO) and member of the executive... ► Artikel lesen | |
| BAYER | 40,790 | +0,12 % | Bayer: Das könnte zum Problem werden | Die Bayer-Aktie zeigt nach einer Erholung zuletzt wieder mehr Gegenwind im Chartbild. Im Fokus steht nun, ob sich die Erholung fortsetzen kann oder der Druck zunimmt Den vollständigen Artikel lesen... ► Artikel lesen | |
| MERCK KGAA | 115,55 | -1,37 % | Eon will Heidelberg-Materials-Chef und Merck-Finanzchefin in den Aufsichtsrat holen | DJ Eon will Heidelberg-Materials-Chef und Merck-Finanzchefin in den Aufsichtsrat holen
DOW JONES--Der Netzbetreiber Eon will zwei hochrangige Manager in seinen Aufsichtsrat holen. Die Hauptversammlung... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 12,500 | 0,00 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | |
| PFIZER | 23,095 | +0,24 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Chris Schott sieht für die Ziele des Pharmaherstellers Luft... ► Artikel lesen | |
| NOVARTIS | 127,66 | -0,90 % | UBS stuft NOVARTIS AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Novartis mit einem Kursziel von 116 Franken auf "Neutral" belassen. Mit seinen Schätzungen für Umsatz und operatives Ergebnis... ► Artikel lesen | |
| LB PHARMACEUTICALS | 29,115 | +9,58 % | Craig-Hallum initiates LB Pharmaceuticals stock coverage with buy rating | ||
| ELI LILLY | 772,90 | +0,76 % | SAP weiter unter Beschuss, Amazon verspricht hohe KI-Umsätze, Eli Lilly schmiedet neue Partnerschaft und TUI sagt weitere Kreuzfahrten ab | Aus dem ganz großen Turnaround ist an der Börse erstmal nichts geworden. Zu brüchig ist die Waffenruhe im Nahen Osten. Bis jetzt hat sie zwar gehalten, doch scheinen gleichzeitig nur wenige Schiffe... ► Artikel lesen | |
| OMNIAB | 1,480 | 0,00 % | OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026 | ||
| MILESTONE PHARMACEUTICALS | 2,195 | 0,00 % | Milestone Pharmaceuticals initiiert Real-World-Studie für PSVT-Medikament CARDAMYST | ||
| ATRIUM THERAPEUTICS | 14,530 | 0,00 % | Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform
Lead candidates ATR 1072... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 26,970 | 0,00 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| GRACE THERAPEUTICS | 4,360 | 0,00 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 | PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage... ► Artikel lesen |
Das Unternehmen ONCOZENGE AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,539 Euro und damit +2,28 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOZENGE AB finden Sie auf Wallstreet Online.